Celltrion will establish a CRDMO subsidiary in Korea by the end of this year and first build a production facility with a ...

Celltrion's strategy focuses on developing and manufacturing biosimilars, which are generic versions of biologic drugs. Its current flagship drugs include biosimilars to Remicade, Rituxan ...

Celltrion has finally merged with Celltrion Healthcare, three years after its original plan was announced. Celltrion announced that its board had approved the merger on Thursday. Each share of ...

Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers ...

Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization ...

TORONTO, March 27, 2025--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced that Remdantry™ will be available in Canada as of April 1, 2025. Remdantry ...

INCHEON, South Korea, May 21, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for YUFLYMA ...

The presentations reflect Celltrion's continued commitment to making comprehensive clinical and real-world evidence accessible to healthcare professionals in the U.S., supporting informed ...

Celltrion, which completed its merger with Celltrion Healthcare in December last year, had been set to merge with Celltrion Pharm, the drugmaker’s domestic distributor and chemical drug development ...

Celltrion recently confirmed that it proved the effectiveness of its subcutaneous infliximab biosimilar, RemsimaSC (CT-P13 SC) in two global Phase III trials. The Phase III study was a 54-week ...